Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONNASDAQ:BACKNASDAQ:BTTXNASDAQ:NIVF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.44+0.4%$7.43$6.20▼$3,499.51$4.33M1.2157,555 shs18,449 shsBACKIMAC$0.04+6.3%$0.04$0.03▼$3.49$88K2.08436,034 shs12,542 shsBTTXBetter Therapeutics$0.00$0.00▼$0.03$5K0.9517,979 shs6 shsNIVFNewGenIvf Group$1.70-5.0%$3.05$1.50▼$656.00$896K0.13801,042 shs744,277 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion-3.64%+10.19%+1.23%-64.45%-99.73%BACKIMAC-12.85%-2.44%+26.58%-92.97%-98.58%BTTXBetter Therapeutics0.00%0.00%-66.67%-50.00%-98.89%NIVFNewGenIvf Group-9.60%-22.17%-46.41%-83.27%-99.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion2.4816 of 5 stars3.05.00.00.03.00.00.6BACKIMACN/AN/AN/AN/AN/AN/AN/AN/ABTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANIVFNewGenIvf Group1.7892 of 5 stars0.04.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.00Hold$11,758.50157,944.35% UpsideBACKIMAC 0.00N/AN/AN/ABTTXBetter Therapeutics 0.00N/AN/AN/ANIVFNewGenIvf Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NIVF, ACON, BACK, and BTTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025ACONAclarionAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$54.60K79.30N/AN/A($125.39) per share-0.06BACKIMAC$72.05K1.22N/AN/A($0.66) per share-0.06BTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/ANIVFNewGenIvf Group$5.43M0.16$0.55 per share3.11$2.19 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$4.91MN/A0.00N/AN/A-12,845.05%-422.87%-201.15%8/13/2025 (Estimated)BACKIMAC-$9.42MN/A0.00∞N/AN/AN/A-325.44%8/4/2025 (Estimated)BTTXBetter Therapeutics-$39.76MN/A0.00N/AN/AN/AN/AN/A7/21/2025 (Estimated)NIVFNewGenIvf Group$130KN/A0.00∞N/AN/AN/AN/AN/ALatest NIVF, ACON, BACK, and BTTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACONAclarion-$1,447.20-$9.32+$1,437.88-$9.32$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/ABACKIMACN/AN/AN/AN/AN/ABTTXBetter TherapeuticsN/AN/AN/AN/AN/ANIVFNewGenIvf GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A2.802.80BACKIMACN/A0.080.08BTTXBetter TherapeuticsN/AN/AN/ANIVFNewGenIvf GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%BACKIMAC5.84%BTTXBetter Therapeutics34.00%NIVFNewGenIvf Group66.24%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%BACKIMAC12.26%BTTXBetter Therapeutics51.40%NIVFNewGenIvf Group31.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7582,000505,000Not OptionableBACKIMAC1802.07 million1.82 millionNot OptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionableNIVFNewGenIvf GroupN/A527,000346,000N/ANIVF, ACON, BACK, and BTTX HeadlinesRecent News About These CompaniesNewGen announces $45 million strategic investment in UAE real estate marketJune 12 at 12:10 PM | kalkinemedia.comNewGen Announces Planned US$45 Million Strategic Investment in UAE Real Estate MarketJune 12 at 7:30 AM | globenewswire.comBRIEF-NewGenIvf Group Files For Offering Of 22.02 Million Class A Ordinary Shares By Selling StockholdersJune 5, 2025 | sg.finance.yahoo.comNewGenIvf Group Announces Planned $30M Strategic Investment in Solana StakingJune 4, 2025 | uk.investing.comNewGenIvf Plans To Invest $30 Mln In SolanaJune 4, 2025 | nasdaq.comNewGenIvf Group Secures $3.2 Million in Debt FinancingJune 4, 2025 | tipranks.comNewGenIvf Group Ltd.June 2, 2025 | wsj.comNewGen Doubles Down on Solana with $30 Million SOL Staking StrategyJune 2, 2025 | coingape.comNewGenIvf Group Limited Announces $30 Million Investment in Solana to Expand Digital Asset StrategyJune 2, 2025 | quiverquant.comNewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset StakingJune 2, 2025 | globenewswire.comNIVF NewGenIvf Group LimitedMay 30, 2025 | seekingalpha.comNewGen Announces Strategic Expansion with Services Tailored for Indian Medical TouristsMay 27, 2025 | finance.yahoo.comNewGenIVF Introduces NewGenSort to Support Men’s Reproductive Health Across AsiaMay 7, 2025 | finance.yahoo.comNewGenIVF Announces Reverse Stock SplitMay 1, 2025 | globenewswire.comNewGenIvf Group reports FY24 EPS (64c) vs. $3.53 last yearApril 23, 2025 | markets.businessinsider.comNewGenIvf Group Limited Files Annual Report for Fiscal Year 2024, Highlights Strong Financial PositionApril 22, 2025 | quiverquant.comNewGen Filed 2024 Annual Report on Form 20-FApril 22, 2025 | globenewswire.comBRIEF-Newgenivf Group-On April 15, Approved Reverse Stock Split Of All Of Co’S Issued And Unissued SharesApril 16, 2025 | sg.finance.yahoo.comNewGenIvf Group secures $5.2M in funding to drive international expansionApril 3, 2025 | markets.businessinsider.comNewGen Secures Strategic Funding to Drive International Expansion and Corporate GrowthApril 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherNVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesUber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo PartnershipBuy the Dip? 3 Oil Stocks Poised for a Big ComebackBy Chris Markoch | May 22, 2025View Buy the Dip? 3 Oil Stocks Poised for a Big ComebackNIVF, ACON, BACK, and BTTX Company DescriptionsAclarion NASDAQ:ACON$7.44 +0.03 (+0.40%) Closing price 03:59 PM EasternExtended Trading$7.52 +0.09 (+1.14%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.IMAC NASDAQ:BACK$0.04 +0.00 (+6.25%) As of 03:52 PM EasternIMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Franklin, Tennessee.Better Therapeutics NASDAQ:BTTXBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.NewGenIvf Group NASDAQ:NIVF$1.70 -0.09 (-5.03%) Closing price 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.88%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
